RT Journal Article
SR Electronic
T1 Using Capture-Recapture Methods to Estimate Influenza Hospitalization Incidence Rates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.03.20225482
DO 10.1101/2020.11.03.20225482
A1 Balasubramani, GK
A1 Nowalk, Mary Patricia
A1 Clarke, Lloyd G.
A1 Dauer, Klancie
A1 Silveira, Fernanda
A1 Middleton, Donald B.
A1 Yassin, Mohamed
A1 Zimmerman, Richard K.
YR 2021
UL http://medrxiv.org/content/early/2021/09/10/2020.11.03.20225482.abstract
AB Background Accurate population estimates of disease incidence and burden are needed to set appropriate public health policy. The capture-recapture (C-R) method combines data from multiple sources to provide better estimates than is possible using single sources.Methods Data were derived from clinical virology test results and from an influenza vaccine effectiveness study from seasons 2016-2017 to 2018-2019. The Petersen C-R method was used to estimate the population size of influenza cases; these estimates were then used to calculate adult influenza hospitalization burden using a Centers for Disease Control and Prevention (CDC) multiplier method.Results Over all seasons, 343 influenza cases were reported in the clinical database and 313 in the research database. Fifty-nine cases (17%) reported in the clinical database were not captured in the research database, and 29 (9%) cases in the research database were not captured in the clinical database. Influenza hospitalizations were higher among vaccinated (58%) than the unvaccinated (35%) in the current season and were similar among unvaccinated (51%) and vaccinated (49%) in the previous year. Completeness of the influenza hospitalization capture was estimated to be 76%. The incidence rates for influenza hospitalizations varied by age and season and averaged 307-309 cases/100,000 adult population annually.Conclusion Using Capture-Recapture methods with more than one database, along with a multiplier method with adjustments improves the population estimates of influenza disease burden compared with relying on a single data source.Competing Interest StatementDrs. Nowalk and Balasubramani, and Mr. Lyons have grant funding from Merck & Co., Inc. for an unrelated project. Dr. Zimmerman has grant funding from Sanofi Pasteur and Merck & Co., Inc. Dr. Silveira has grant funding from Shire, Ansun, Novartis for unrelated projects. Dr. Middleton reports personal fees from Seqirus, grants and personal fees from Pfizer, personal fees from Sanofi Pasteur. Dr. Yassin and Mr. Clarke have no conflicts to report.Clinical TrialThis study was not registered with clinicaltrials.gov because it is a data analysis from an observational study.Funding StatementThis work was supported by the Centers for Disease Control and Prevention (CDC) [5U01IP001035-02] and by National Institutes of Health (NIH) [UL1TR001857].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Pittsburgh IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be made available at the end of the cooperative agreement, with CDC's permission.